Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 19/20 | 0.89 |
| ▸ | CASP7 | P55210 | 13/20 | 0.89 |
| ▸ | CASP1 | P29466 | 7/20 | 0.89 |
| ▸ | CASP4 | P49662 | 3/20 | 0.89 |
| ▸ | CASP9 | P55211 | 5/20 | 0.80 |
| ▸ | CASP10 | Q92851 | 3/20 | 0.73 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.68 |
| ▸ | CASP5 | P51878 | 1/20 | 0.63 |
| ▸ | CASP6 | P55212 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15462711 | 1.00 | CASP3 (0.89) | CASP3CASP7CASP1CASP4CASP9 | |
| SCHEMBL7886294 | 0.94 | CASP3 (1.00) | CASP3CASP7CASP1CASP4CASP9 | |
| SCHEMBL9962013 | 0.90 | CASP3 (0.88) | CASP3CASP7CASP1CASP4CASP9 | |
| SCHEMBL15462714 | 0.90 | CASP3 (0.85) | CASP3CASP7CASP1CASP4CASP9 | |
| SCHEMBL20356080 | 0.90 | CASP3 (0.85) | CASP3CASP7CASP1CASP4CASP9 | |
| SCHEMBL9962404 | 0.89 | CASP3 (0.89) | CASP3CASP7CASP1CASP4CASP9 | |
| SCHEMBL7882808 | 0.89 | CASP3 (0.89) | CASP3CASP7CASP1CASP4CASP9 | |
| SCHEMBL15462634 | 0.89 | CASP3 (0.74) | CASP3CASP7CASP1CASP4CASP9 | |
| SCHEMBL7887169 | 0.89 | CASP3 (1.00) | CASP3CASP7CASP1CASP4CASP9 | |
| SCHEMBL9962188 | 0.89 | CASP3 (0.88) | CASP3CASP7CASP1CASP4CASP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975119-B2 | Selective cysteine protease inhibitors and uses thereof | GENESIS TECHNOLOGIES LIMITED (BB) | 2021-04-13 | — | — | US | disclosed |
| US-20180186833-A1 | SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | GENESIS TECH LIMITED (BB) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186833-A1 | SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | SERPINB1, SERPINE1, CASP5 | CASP3 146/4885CASP7 102/4885CASP1 25/4885 |
| US-10975119-B2 | Selective cysteine protease inhibitors and uses thereof | SERPINB1, SERPINE1, CASP5 | CASP3 171/4885CASP7 129/4885CASP1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.